Gastrointestinal bleeding among oral anticoagulant users: a comprehensive 7-year retrospective review using Türkiye's national health data system.

IF 1.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Turkish Journal of Medical Sciences Pub Date : 2024-07-10 eCollection Date: 2024-01-01 DOI:10.55730/1300-0144.5879
Nuray Yilmaz Çakmak, Naim Ata, Serdar Can Güven, Emin Gemcioğlu, Murat Çağlayan, Mahir Ülgü, Şuayip Birinci
{"title":"Gastrointestinal bleeding among oral anticoagulant users: a comprehensive 7-year retrospective review using Türkiye's national health data system.","authors":"Nuray Yilmaz Çakmak, Naim Ata, Serdar Can Güven, Emin Gemcioğlu, Murat Çağlayan, Mahir Ülgü, Şuayip Birinci","doi":"10.55730/1300-0144.5879","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>The comparative risk of gastrointestinal bleeding (GIB) among users of direct-acting oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) is a topic of ongoing debate. This study leverages a comprehensive national health database to evaluate the incidence of GIB, associated risk factors, and postbleeding management strategies among anticoagulated patients.</p><p><strong>Materials and methods: </strong>Utilizing the Turkish Ministry of Health's e-Nabız system, we conducted a retrospective analysis of patients treated with DOACs and warfarin from January 2017 to July 2023. GIB events were identified using ICD codes, and comorbidities, prior medication use, interventions, and mortality rates were analyzed. Drug survival and patterns of changes following GIB were also evaluated.</p><p><strong>Results: </strong>Among 102,545 patients with a GIB event during anticoagulant treatment, DOAC users were older with a higher prevalence of comorbidities, except for chronic obstructive lung disease, compared to VKA users. GIB-related mortality was 0.6% in the DOAC group and 0.4% in the VKA group at admission after the GIB (p < 0.01). In all drug groups, approximately half of the patients discontinued anticoagulation due to GIB after 3 months, the rate being highest with apixaban (61.9%). In patients who continued anticoagulation, the anticoagulant prior to GIB remained the most common agent in all groups, with rivaroxaban having the highest retention rate (40.7%).</p><p><strong>Conclusion: </strong>This nationwide study indicates a higher frequency of GIB in DOAC users versus VKA users, with age and comorbidities potentially contributing to this trend. Mortality rates were comparable to the previous literature but warrant further investigation. The significant rate of discontinuation following GIB raises concerns about ongoing anticoagulation management. These findings underscore the need for cautious case management.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 5","pages":"1005-1012"},"PeriodicalIF":1.2000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518346/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55730/1300-0144.5879","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aim: The comparative risk of gastrointestinal bleeding (GIB) among users of direct-acting oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) is a topic of ongoing debate. This study leverages a comprehensive national health database to evaluate the incidence of GIB, associated risk factors, and postbleeding management strategies among anticoagulated patients.

Materials and methods: Utilizing the Turkish Ministry of Health's e-Nabız system, we conducted a retrospective analysis of patients treated with DOACs and warfarin from January 2017 to July 2023. GIB events were identified using ICD codes, and comorbidities, prior medication use, interventions, and mortality rates were analyzed. Drug survival and patterns of changes following GIB were also evaluated.

Results: Among 102,545 patients with a GIB event during anticoagulant treatment, DOAC users were older with a higher prevalence of comorbidities, except for chronic obstructive lung disease, compared to VKA users. GIB-related mortality was 0.6% in the DOAC group and 0.4% in the VKA group at admission after the GIB (p < 0.01). In all drug groups, approximately half of the patients discontinued anticoagulation due to GIB after 3 months, the rate being highest with apixaban (61.9%). In patients who continued anticoagulation, the anticoagulant prior to GIB remained the most common agent in all groups, with rivaroxaban having the highest retention rate (40.7%).

Conclusion: This nationwide study indicates a higher frequency of GIB in DOAC users versus VKA users, with age and comorbidities potentially contributing to this trend. Mortality rates were comparable to the previous literature but warrant further investigation. The significant rate of discontinuation following GIB raises concerns about ongoing anticoagulation management. These findings underscore the need for cautious case management.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
口服抗凝剂使用者中的消化道出血:利用土耳其国家健康数据系统进行的为期 7 年的全面回顾。
背景/目的:直接作用口服抗凝药(DOACs)与维生素 K 拮抗剂(VKAs)使用者发生胃肠道出血(GIB)的风险比较一直是一个争论不休的话题。本研究利用一个全面的国家卫生数据库,评估抗凝患者中 GIB 的发生率、相关风险因素和出血后管理策略:利用土耳其卫生部的 e-Nabız 系统,我们对 2017 年 1 月至 2023 年 7 月期间接受 DOACs 和华法林治疗的患者进行了回顾性分析。我们使用 ICD 代码识别了 GIB 事件,并分析了合并症、之前的用药情况、干预措施和死亡率。此外,还评估了 GIB 后的药物存活率和变化模式:在 102,545 名在抗凝治疗期间发生 GIB 事件的患者中,与 VKA 使用者相比,DOAC 使用者年龄较大,合并症(慢性阻塞性肺病除外)发生率较高。GIB发生后入院时,DOAC组与GIB相关的死亡率为0.6%,VKA组为0.4%(P < 0.01)。在所有药物组中,约有一半的患者在 3 个月后因 GIB 而停止抗凝,其中阿哌沙班的停药率最高(61.9%)。在继续抗凝的患者中,GIB发生前的抗凝剂仍然是所有组别中最常用的药物,其中利伐沙班的保留率最高(40.7%):这项全国性研究表明,DOAC使用者发生GIB的频率高于VKA使用者,年龄和合并症可能是导致这一趋势的原因。死亡率与之前的文献不相上下,但值得进一步研究。GIB 后的显著停药率引起了人们对持续抗凝管理的关注。这些发现强调了谨慎管理病例的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Turkish Journal of Medical Sciences
Turkish Journal of Medical Sciences 医学-医学:内科
CiteScore
4.60
自引率
4.30%
发文量
143
审稿时长
3-8 weeks
期刊介绍: Turkish Journal of Medical sciences is a peer-reviewed comprehensive resource that provides critical up-to-date information on the broad spectrum of general medical sciences. The Journal intended to publish original medical scientific papers regarding the priority based on the prominence, significance, and timeliness of the findings. However since the audience of the Journal is not limited to any subspeciality in a wide variety of medical disciplines, the papers focusing on the technical  details of a given medical  subspeciality may not be evaluated for publication.
期刊最新文献
Hematological diseases and the heart. Transition of patients with systemic lupus erythematosus from pediatric to adult-oriented rheumatology care. Evaluation of single-layer versus double-layer suturing of low transverse uterine incisions in cesarean section and follow-up of scars by ultrasound: a prospective randomized controlled study. The difference between clinical significance and statistical significance: an important distinction for clinical research. Cardiac effects and comorbidities of neurological diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1